🇺🇸 FDA
Pipeline program

SRP-9004

9004-101

Phase 2 gene_therapy completed

Quick answer

SRP-9004 for Limb-Girdle Muscular Dystrophy, Type 2D is a Phase 2 program (gene_therapy) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Sarepta Therapeutics
Indication
Limb-Girdle Muscular Dystrophy, Type 2D
Phase
Phase 2
Modality
gene_therapy
Status
completed

Clinical trials